APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42

被引：117

作者：

Prince, JA

Zetterberg, H ^{[1
]}

Andreasen, N

Marcusson, J

Blennow, K

机构：

[1] Gothenburg Univ, Sahlgrenska Univ Hosp, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden

[2] Karolinska Inst, Ctr Genom & Bioinformat, Stockholm, Sweden

[3] Huddinge Univ Hosp, Karolinska Inst, Neurotec, S-14186 Huddinge, Sweden

[4] Linkoping Univ Hosp, Dept Geriatr Med, Linkoping, Sweden

[5] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Expt Neurosci, Inst Clin Neurosci, Molndal, Sweden

来源：

NEUROLOGY | 2004年 / 62卷 / 11期

关键词：

D O I：

10.1212/01.WNL.0000128088.08695.05

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The epsilon4 allele of APOE is a risk factor for Alzheimer disease (AD). By analysis of a large cohort of AD patients (n = 563) and control subjects (n = 118), it is shown that the epsilon4 allele is strongly associated with reduced CSF levels of beta-amyloid (1-42) (Abeta42) in both AD (p < 10(-9)) and control (p = 0.0012) populations. As no associations of APOE variants with other indexes of AD severity were observed, this effect may reflect a fundamental involvement of ApoE in A beta metabolism.

引用

页码：2116 / 2118

页数：3

共 10 条

[1] CSF markers for incipient Alzheimer's disease
Blennow, K
Hampel, H
[J]. LANCET NEUROLOGY, 2003, 2 (10) : 605 - 613
[2] No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
Blennow, K
Ricksten, A
Prince, JA
Brookes, AJ
Emahazion, T
Wasslavik, C
Bogdanovic, N
Andreasen, N
Båtsman, S
Marcusson, J
Nägga, K
Wallin, A
Regland, B
Olofsson, H
Hesse, C
Davidson, P
Minthon, L
Jansson, A
Palmqvist, L
Rymo, L
[J]. JOURNAL OF NEURAL TRANSMISSION, 2000, 107 (8-9) : 1065 - 1079
[3] Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease
Fagan, AM
Watson, M
Parsadanian, M
Bales, KR
Paul, SM
Holtzman, DM
[J]. NEUROBIOLOGY OF DISEASE, 2002, 9 (03) : 305 - 318
[4] High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
Galasko, D
Chang, L
Motter, R
Clark, CM
Kaye, J
Knopman, D
Thomas, R
Kholodenko, D
Schenk, D
Lieberburg, I
Miller, B
Green, R
Basherad, R
Kertiles, L
Boss, MA
Seubert, P
[J]. ARCHIVES OF NEUROLOGY, 1998, 55 (07) : 937 - 945
[5] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
Hulstaert, F
Blennow, K
Ivanoiu, A
Schoonderwaldt, HC
Riemenschneider, M
De Deyn, PP
Bancher, C
Cras, P
Wiltfang, J
Mehta, PD
Iqbal, K
Pottel, H
Vanmechelen, E
Vanderstichele, H
[J]. NEUROLOGY, 1999, 52 (08) : 1555 - 1562
[6] Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice
Ji, Yong
Permanne, Bruno
Sigurdsson, Einar M.
Holtzman, David M.
Wisniewski, Thomas
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2001, 3 (01) : 23 - 30
[7] Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease
Mehta, PD
Pirttilä, T
Mehta, SP
Sersen, EA
Aisen, PS
Wisniewski, HM
[J]. ARCHIVES OF NEUROLOGY, 2000, 57 (01) : 100 - 105
[8] REDUCTION OF BETA-AMYLOID PEPTIDE(42), IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH ALZHEIMERS-DISEASE
MOTTER, R
VIGOPELFREY, C
KHOLODENKO, D
BARBOUR, R
JOHNSONWOOD, K
GALASKO, D
CHANG, L
MILLER, B
CLARK, C
GREEN, R
OLSON, D
SOUTHWICK, P
WOLFERT, R
MUNROE, B
LIEBERBURG, I
SEUBERT, P
SCHENK, D
[J]. ANNALS OF NEUROLOGY, 1995, 38 (04) : 643 - 648
[9] Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): Design criteria and assay validation
Prince, JA
Feuk, L
Howell, WM
Jobs, M
Emahazion, T
Blennow, K
Brookes, AJ
[J]. GENOME RESEARCH, 2001, 11 (01) : 152 - 162
[10] APOLIPOPROTEIN-E - A PATHOLOGICAL CHAPERONE PROTEIN IN PATIENTS WITH CEREBRAL AND SYSTEMIC AMYLOID
WISNIEWSKI, T
FRANGIONE, B
[J]. NEUROSCIENCE LETTERS, 1992, 135 (02) : 235 - 238

← 1 →